1. Humacyte secures a $77.5 million credit facility from Avenue Venture. 2. Initial $40 million tranche helps retire existing debt. 3. Plans for expanding Symvess in U.S. and international markets. 4. Upcoming Phase 3 trial results expected in 2026. 5. Humacyte's FDA approvals enhance market potential for its products.
FAQ
Why Bullish?
The credit facility reduces existing debt and supports growth plans. Historical trends show financing success correlates with stock rises in biotech.
How important is it?
The financing announcement directly impacts Humacyte's financial stability and growth trajectory. Strong market response to biotechnology advancements supports the stock's future performance.
Why Long Term?
The facility enables ongoing operations and product development, leading to sustained growth. Previous FDA approval cycles showed long-term stock benefits.
Humacyte Secures Credit Facility of Up to $77.5 Million with Avenue Capital
DURHAM, N.C., December 16, 2025 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a biotechnology company acclaimed for its innovations in bioengineered human tissues, has announced the establishment of a credit facility with Avenue Venture Opportunities Fund II, L.P. This newly secured financing can provide up to $77.5 million in principal amount over four years, facilitating the company's strategic growth and operational plans.
Details of the Credit Facility Agreement
The credit facility comprises an initial tranche of $40 million, which will be fully funded at close. Additionally, there are two subsequent tranches available, with a combined potential of $37.5 million subject to specific performance benchmarks, regulatory approvals, and lender consent. Proceeds from the initial funding will primarily be utilized to settle existing debt.
"We are pleased to enter into this facility with Avenue as it allows us to retire our existing indebtedness while providing the opportunity for additional non-dilutive financing in the future," stated Dale Sander, Chief Financial Officer of Humacyte.
Future Growth and Plans for Humacyte (HUMA)
Looking forward to 2026, Humacyte has ambitious plans, which include expanding the market for its flagship product, Symvess®, both in the U.S. and internationally. The company also anticipates interim results from its ongoing V012 Phase 3 clinical trial focused on dialysis and the initiation of its first human study for the coronary tissue engineered vessel (CTEV) in bypass graft surgery.
Chad Norman, Senior Portfolio Manager at Avenue Venture Opportunities Fund, remarked, "We are excited to partner with Humacyte as it embarks on its next chapter of growth. Symvess addresses significant patient needs, and we look forward to supporting them in achieving success."
About Avenue Venture Opportunities Fund
Avenue Venture Opportunities Fund aims to offer innovative financing solutions to high-growth, venture-backed technology and life sciences companies. This fund focuses on bridging the financing gap that exists between commercial banking and larger debt financing avenues, offering much-needed support to companies in the industry.
Overview of Humacyte, Inc. (HUMA)
Humacyte, Inc. (Nasdaq: HUMA) is at the forefront of biotech innovation, specializing in the production of universally implantable bioengineered human tissues and advanced tissue constructs intended to enhance patient outcomes and revolutionize medical practices.
- The FDA approved Humacyte's Biologics License Application for its acellular tissue engineered vessel (ATEV) for vascular trauma in December 2024.
- The ATEV is undergoing late-stage clinical trials for several applications, including hemodialysis access and peripheral artery disease (PAD).
- Preclinical developments are also in motion for coronary artery bypass grafts and treatments for type 1 diabetes.
- The ATEV has received notable FDA designations, including Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations.
For uses outside the approved vascular trauma indication, the ATEV remains investigational and is not yet available for commercial sale.
Forward-Looking Statements
This announcement contains forward-looking statements that involve risks and uncertainties, which may lead to actual results differing materially from those anticipated. Important factors include market acceptance of Humacyte's products and the successful execution of its development plans. For more details on risks, refer to the company's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024, and Form 10-Q for the quarter ended September 30, 2025.